Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,671.88
(
-0.66%
)
US TECH 100
24,029.20
(
-0.43%
)
Dow Jones
46,553.32
(
-0.94%
)
Brent Oil
105.66
(
4.97%
)
Bitcoin
71,093.67
(
-3.85%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 133642

Thursday, 12/22/2011 8:23:40 PM

Thursday, December 22, 2011 8:23:40 PM

Post# of 257253

Given the much lower % sales dollars flowing to Momenta (than for Copaxone) apparently big pharma and Momenta either:
1) Disagree with your assertion above
OR
2) Don't think Momenta will be sole substitutible
OR
3) Don't think Momenta will get fully substitutible at all and will thus be just one of the multitudes of non-subs biosimilars.

What does the Copaxone deal have to do with any of this? Copaxone is sui generis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now